Sotaleks - instructions for use, analogs, reviews and release forms (tablets 160 mg) of the drug for arrhythmia, tachycardia and tachyarrhythmia in adults, children and pregnancy

In this article, you can read the instructions for using the drug Sotaleks. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Sotalex in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Sotalex in the presence of existing structural analogs. Use for the treatment of arrhythmia, tachycardia and tachyarrhythmias in adults, children, as well as during pregnancy and lactation.

Sotaleks - a non-selective beta-blocker acting on beta1 and beta2-adrenergic receptors. Has a pronounced antiarrhythmic effect, the mechanism of which is to increase the duration of the action potential and the lengthening of the absolute refractory period in all parts of the cardiac conduction system (class 3 antiarrhythmic drugs). Reduces heart rate and contractility of the myocardium, slows AV-conduction, reduces the absolute refractory period. Blocking beta2-adrenoreceptors, increases the tone of the smooth muscles of the bronchi, vessels.

Composition

Sotalol hydrochloride + excipients.

Pharmacokinetics

Bioavailability of Sotalex is 90-100%. Sotalol does not bind to plasma proteins and is not metabolized in the body. 80-90% of the accepted dose is excreted unchanged in the urine, the rest - with feces.

Indications

• supraventricular tachyartmias accompanied by clinical symptoms (including atrioventricular (nodular) paroxysmal tachycardias in WPW syndrome or paroxysmal atrial fibrillation arrhythmias);
• maintaining a normal sinus rhythm after arresting flicker or atrial flutter;
• severe ventricular arrhythmias accompanied by severe clinical symptoms (tachyarrhythmias) and their prophylaxis with proven efficacy;
• arrhythmias caused by excessive circulation of catecholamines or hypersensitivity to catecholamines.

Forms of release

Tablets 160 mg.

Instructions for use and dosing regimen

In the treatment of tachyarrhythmias, the recommended initial single dose is 40 mg; the frequency of reception is 2 times a day. The recommended daily dose is 160-320 mg. If necessary, it is possible to increase the dose to 160 mg three times a day.

In patients with impaired renal function, the dose of the drug is adjusted depending on the values ​​of creatinine clearance. With QA 30-10 ml / min (serum creatinine 2.5 mg / dl), a dose reduction of half is recommended; with SC less than 10 ml / min (serum creatinine> 5 mg / dL), the recommended dose is 1/4 of the mean.

The drug is recommended to be taken before meals.

Side effect

• bradycardia;
• AV blockade;
• increased symptoms of heart failure;
• arterial hypotension;
• increased attacks of angina pectoris;
• nausea;
• diarrhea;
• constipation;
• dry mouth;
• headache;
• dizziness;
• fatigue;
• drowsiness;
• paresthesia;
• sleep disturbance;
• depression;
• violation of visual acuity;
• inflammation of the cornea and conjunctiva;
• syncopal states;
• bronchospasm;
• sexual dysfunction;
• skin rash;
• itching;
• coldness of limbs;
• muscle weakness.

Contraindications

• chronic heart failure 2B-3 stage;
• shock;
• arterial hypotension;
• AV-blockade of 2 and 3 degrees;
• sinoatrial blockade;
• SSSU;
• bradycardia;
• prolongation of the QT interval;
• obliterating vascular diseases;
• obstructive airway disease;
• metabolic acidosis;
• laryngeal edema;
• severe allergic rhinitis;
• untreated pheochromocytoma;
• hypersensitivity to the drug and sulfonamides.

Application in pregnancy and lactation

Application Sotaleksa during pregnancy and lactation (breastfeeding) is possible only for life indications.

special instructions

With caution apply the drug in patients who recently suffered a myocardial infarction with diabetes, pheochromocytoma, psoriasis, as well as in patients with impaired renal function. Treatment with Sotalex is performed under the control of heart rate, blood pressure, ECG.

With the withdrawal of the drug, its dose should be reduced gradually; special care should be taken when discontinuing Sotalex therapy in patients with coronary artery disease and with heart rhythm disorders, as well as with prolonged use of the drug. The question of abolishing or changing the dosage regimen of the drug in patients with life-threatening disturbances of the heart rhythm can be solved only by the doctor.

During the period of Sotalex's application, patients who underwent myocardial infarction or patients with impaired contractility of the myocardium should be supervised by a cardiologist.

Impact on the ability to drive vehicles and manage mechanisms

With caution appoint the drug to patients engaged in potentially hazardous activities that require increased attention and speed of psychomotor reactions.

Drug Interactions

With the simultaneous use of Sotalex with calcium antagonists (verapamil, diltiazem) there is an additive inhibitory effect on the sinus and atrioventricular nodes (caution should be exercised when they are used simultaneously).

With the simultaneous use of Sotalex with class 1 antiarrhythmics, prolonging the QT interval (drugs like quinidine), the risk of ventricular arrhythmias increases (this combination should be avoided).

With the simultaneous use of Sotalex with antiarrhythmic agents of the 3rd class, as well as with astemizole, terfenadine, halofantrine, the risk of excessive prolongation of the QT interval increases (Sotalex should be avoided in combination with these drugs).

With the simultaneous use of Sotalex with calcium antagonists and antihypertensive drugs, with some tranquilizers, hypnotics (tricyclic antidepressants, barbiturates, phenothiazines, opioid analgesics), with diuretics and vasodilators, a significant drop in blood pressure is possible.

The negative chronotropic action of Sotalex, as well as the slowing of AV conduction caused by it, can be intensified by simultaneous application with reserpine, clonidine, alpha-methyldopa, guanfacin or with cardiac glycosides.

With the simultaneous use of Sotalex with insulin or oral hypoglycemic drugs, especially with increased physical exertion,possibly lowering blood glucose levels or increasing symptoms of hypoglycemia.

Analogues of the drug Sotaleks

Structural analogs for the active substance:

• Darub;
• SotaGexal;
• Sotalol Canon;
• Sotalol hydrochloride.

Similar medicines:

Other medicines: